When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

The world's first robotic transcatheter aortic valve replacement (TAVR) explant and aortic valve replacement took place at ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

A new method, based on the use of molecules known as polypurine hairpins, facilitates the uptake of cholesterol by cells and ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Researchers gave participants three different doses. At 0.3 mg/kg, patients saw a 21% reduction in LDL cholesterol. At 0.45 ...

Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...

Merck (MRK) on Monday announced positive results from the first two of three late-stage clinical trials evaluating the safety ...